Company intelligence / Profile preview

RWD Acquisition I

Clearwater, Florida, United States

Ownership: Private
Development stage: Other

Overview

RWD Acquisition I LLC is a private investment vehicle and holding company founded and led by billionaire biotech investor Robert W. Duggan. The entity is most notable for its role in the 2008 acquisition of a controlling stake in Pharmacyclics, Inc., where Duggan subsequently served as CEO and oversaw the development of the blockbuster cancer drug Imbruvica (ibrutinib). Following the $21 billion sale of Pharmacyclics to AbbVie in 2015, the vehicle has continued to serve as a platform for Duggan's strategic investments in the life sciences sector. Currently, Duggan is the CEO and largest shareholder of Summit Therapeutics, and RWD Acquisition I remains a key entity in his investment portfolio.

Industry: Investors

Beyond the preview

Go deeper on RWD Acquisition I.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RWD Acquisition I.

Explore the full profile